Project Number 1R01AG071810-01 Agency/Funding Organization NIA Funding Year 2021 View Full Project Details for First-in-Human (Phase 1) Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of IBC-Ab002 in Persons with Early Alzheimer's Disease (AD) Research Categorization Primary Disease / Condition Alzheimer's Disease CADRO Category C. Translational Research and Clinical Interventions 7. Early-stage Clinical Drug Development (Phase I and II Clinical Trials) f. Inflammation Researcher and Organization Principal Investigator YOLES, ETI Principal Investigator First Name ETI Principal Investigator Last Name YOLES Awardee Organization IMMUNOBRAIN CHECKPOINT INC. Awardee State New York, N.Y. Contact PI Country United States Project Detail Funding Opportunity Announcement PAR-18-877: Early Stage Clinical Trials for the Spectrum of Alzheimers Disease and Age-related Cognitive Decline (R01 Clinical Trial Optional) FY Overall Cost $1,984,624 Funding Organization Agency/Funding Organization NIA Funding Organization Country United States Program Official RYAN, LAURIE M
